Picture of Hikma Pharmaceuticals logo

HIK — Hikma Pharmaceuticals Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareBalancedLarge CapNeutral

Momentum

Relative Strength (%)
1m-12.92%
3m-19.87%
6m-27.38%
1yr-28.12%
Volume Change (%)
10d/3m-1.84%
Price vs... (%)
52w High-24.94%
50d MA-9.09%
200d MA-15.66%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)12.72
PEG Ratio (f)1.02
EPS Growth (f)14.22%
Dividend Yield (f)2.18%
Valuation (ttm)IndustryMarket
Price to Book Value2.79
Price to Tang. Book4.61
Price to Free Cashflow35.67
Price to Sales2.63
EV to EBITDA8.72

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital20.25%
Return on Equity22.34%
Operating Margin26.89%

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue$m1,9501,9362,0762,2032,3412,506.512,742.210.21%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+0.31-31.95+92.1+13.41-30.77+26.96+14.22n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for HIK

Are analysts backing shares in Hikma Pharmaceuticals? background image

Are analysts backing shares in Hikma Pharmaceuticals?

Almost every industry sector has been affected in some way by the Covid-19 crisis. For investors, that means there is a lot of uncertainty about which way large-cap stocks like Hikma Pharmaceuticals (LON:HIK) will move over the near te...

Analysts upbeat on the outlook for Hikma Pharmaceuticals background image

Analysts upbeat on the outlook for Hikma Pharmaceuticals

The Hikma Pharmaceuticals (LON:HIK) share price has risen by 2.99% over the past month and it’s currently trading at 2,446p. For investors considering whether to buy, hold or sell the stock, the question now is whether this price run w...

Are analysts backing shares in Hikma Pharmaceuticals? background image

Are analysts backing shares in Hikma Pharmaceuticals?

Almost every industry sector has been affected in some way by the Covid-19 crisis. For investors, that means there is a lot of uncertainty about which way large-cap stocks like Hikma Pharmaceuticals (LON:HIK) will move over the near te...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Hikma Pharmaceuticals EPS forecast chart

Profile Summary

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company's segments include Branded, Injectables, Generics and Others. The Company provides non-injectable and injectable generic medicines in the United States. It provides branded generic medicines and generic injectable products across the Middle East and North Africa (MENA). It also provides generic injectable medicines in Europe and other markets around the world. The Company's other businesses comprise Arab Medical Containers (AMC), a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Directors

Last Annual
December 31st, 2020
Last Interim
June 30th, 2021
Incorporated
September 8th, 2005
Public Since
November 1st, 2005
No. of Employees
8,681
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
gb flag iconLondon Stock Exchange
Shares in Issue
231,498,055

HIK Share Price Performance

Latest News for HIK

Upcoming Events for HIK

Full Year 2021 Hikma Pharmaceuticals PLC Earnings Release

Hikma Pharmaceuticals PLC Annual Shareholders Meeting

Similar to HIK

Picture of Abcam logo

Abcam

gb flag iconLondon Stock Exchange

Picture of Alliance Pharma logo

Alliance Pharma

gb flag iconLondon Stock Exchange

Picture of Animalcare logo

Animalcare

gb flag iconLondon Stock Exchange

Picture of AstraZeneca logo

AstraZeneca

gb flag iconLondon Stock Exchange

Picture of Benchmark Holdings logo

Benchmark Holdings

gb flag iconLondon Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email